NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

NewAmsterdam Pharma (NAMS) has 3 years of Non-Current Deffered Revenue data on file, last reported at $222000.0 in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Deffered Revenue changed N/A year-over-year to $222000.0; the trailing twelve-month figure through Jun 2024 stood at $222000.0 (changed N/A YoY), and the FY2023 full-year result was $1.0 million, down 78.74% from the prior year.
• Non-Current Deffered Revenue retreated to $222000.0 in Q2 2024, from $444000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $4.8 million in Q4 2022 to a low of $222000.0 in Q2 2024.
• A 3-year average of $1.6 million and a median of $731500.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 78.74% in 2023, while the deepest fall reached 78.74% in 2023.
• Tracing NAMS's Non-Current Deffered Revenue over 3 years: stood at $4.8 million in 2022, then sank by 78.74% to $1.0 million in 2023, then plunged by 78.21% to $222000.0 in 2024.
• Business Quant data shows NAMS's Non-Current Deffered Revenue at $222000.0 in Q2 2024, $444000.0 in Q1 2024, and $1.0 million in Q4 2023.